Twin Capital Management Inc. Takes $916,000 Position in Ralliant Corporation $RAL

Twin Capital Management Inc. purchased a new position in shares of Ralliant Corporation (NYSE:RAL) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 22,022 shares of the company’s stock, valued at approximately $916,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of RAL. Dodge & Cox boosted its stake in Ralliant by 13.3% during the fourth quarter. Dodge & Cox now owns 12,214,679 shares of the company’s stock worth $621,849,000 after buying an additional 1,434,376 shares during the period. Viking Global Investors LP purchased a new position in shares of Ralliant during the 2nd quarter worth approximately $257,200,000. Millennium Management LLC boosted its position in shares of Ralliant by 172.4% during the 4th quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock worth $253,175,000 after purchasing an additional 3,147,660 shares during the period. State Street Corp acquired a new stake in Ralliant in the 2nd quarter valued at approximately $213,096,000. Finally, Invesco Ltd. increased its holdings in Ralliant by 4.9% in the 4th quarter. Invesco Ltd. now owns 4,059,588 shares of the company’s stock valued at $206,674,000 after purchasing an additional 187,898 shares during the last quarter.

Analysts Set New Price Targets

A number of research analysts have commented on RAL shares. Vertical Research cut Ralliant from a “buy” rating to a “hold” rating and set a $65.00 price target on the stock. in a research note on Wednesday, May 27th. Truist Financial reaffirmed a “buy” rating and issued a $68.00 price objective (up from $53.00) on shares of Ralliant in a research note on Wednesday, May 13th. Barclays boosted their price objective on Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a report on Wednesday, May 13th. Weiss Ratings reissued a “sell (d)” rating on shares of Ralliant in a research note on Monday, May 4th. Finally, Zacks Research upgraded Ralliant from a “hold” rating to a “strong-buy” rating in a report on Tuesday, June 30th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $70.80.

Ralliant Stock Performance

NYSE:RAL opened at $66.99 on Friday. Ralliant Corporation has a 52 week low of $37.27 and a 52 week high of $75.41. The company has a fifty day simple moving average of $64.75 and a two-hundred day simple moving average of $53.01. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.73. The company has a market cap of $7.50 billion and a price-to-earnings ratio of -6.12.

Ralliant (NYSE:RAL) last announced its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The business had revenue of $534.60 million for the quarter. The company’s quarterly revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. As a group, equities analysts anticipate that Ralliant Corporation will post 2.64 earnings per share for the current fiscal year.

Ralliant Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th were given a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, June 8th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Ralliant’s payout ratio is currently -1.83%.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.